Suchergebnisse - "Lin, Jianchang"

PubPharm (6)

1

Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2023

von Christopoulos, P. | Prawitz, T. | Hong, J. | +11

2

Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations : An indirect comparison

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2023

von Ou, S. | Lin, H. | Hong, J. | +7

3

Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer

enthalten in: Expert review of anticancer therapy | 2023

von Yang, J. | Zhou, C. | Jänne, P. | +18

4

Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions : Exposure-Response Analyses of a Pivotal Phase I/II Study

enthalten in: Clinical pharmacology and therapeutics | 2022

von Gupta, N. | Largajolli, A. | Witjes, H. | +5

5

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer : A Phase 1/2 Open-label Nonrandomized Clinical Trial

enthalten in: JAMA oncology | 2021

von Zhou, C. | Ramalingam, S. | Kim, T. | +15

ErratumIn: JAMA Oncol. 2022 Feb 24;:. - PMID 35201294

6

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

enthalten in: Cancer discovery | 2021

von Riely, G. | Neal, J. | Camidge, D. | +19

CommentIn: Cancer Discov. 2021 Jul;11(7):1617-1619. - PMID 34284994

1
[1]